Bolus vs IVP (Intravenous Push) Diltiazem for Atrial Fibrillation or Flutter
Launched by MERCY HEALTH MUSKEGON · Oct 24, 2019
Trial Information
Current as of June 20, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be 18 years and older,
- • Present with atrial fibrillation or atrial flutter with a rapid ventricular response
- • Have a 12-lead ECG (electrocardiogram) showing atrial fibrillation or atrial flutter with a rapid ventricular rate greater than 120 beats per minute.
- • Able to provide consent for self, or have a legally authorized representative available to provide consent by proxy.
- • Have a cardiac history not inclusive of the diagnoses listed under exclusion criteria.
- Exclusion Criteria:
- • Altered mental status as a direct result of hemodynamic instability
- • Heart rate \>220 beats per minute
- • 2nd or 3rd degree atrioventricular block
- • QRS (time for ventricular repolarization) \>110 milliseconds
- • Temperature \>38 Celsius
- • Acute STEMI (ST-Elevation Myocardial Infarction)
- • Pulmonary edema
- • Unstable angina
- • Allergy to diltiazem
- • Pregnancy
- • Breastfeeding
- • History of pre-excitation syndrome
- • Decompensated heart failure
- • Incarcerated persons
About Mercy Health Muskegon
Mercy Health Muskegon is a leading healthcare provider dedicated to delivering high-quality medical care and advancing clinical research. As part of the Mercy Health system, this organization integrates compassionate patient care with innovative research initiatives, focusing on improving health outcomes in the community. With a commitment to evidence-based practices, Mercy Health Muskegon sponsors clinical trials that aim to explore new treatment modalities and enhance existing therapies, ensuring that patients benefit from the latest advancements in medical science. The institution emphasizes collaboration among healthcare professionals, researchers, and patients to foster a robust research environment that prioritizes safety, ethics, and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials